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ABSTRACT 
James Byrne: Iontophoretic delivery of cytotoxic agents for the treatment of solid tumors  
(under the direction of Joseph M. DeSimone) 
Parenteral and oral routes have been the traditional methods of administering cytotoxic 
agents to cancer patients. Unfortunately, the maximum potential effect of these cytotoxic agents 
has been limited due to systemic toxicity and poor tumor perfusion. In an attempt to improve the 
efficacy of cytotoxic agents while mitigating their side effects, we have developed modalities for 
the localized iontophoretic delivery of cytotoxic agents. These pressurized, reservoir-based 
iontophoretic devices were designed to be implanted proximal to the tumor with external control 
of power and drug flow. Three distinct orthotopic mouse models of cancer and a canine model 
were evaluated for device efficacy and toxicity. In the mouse models, device delivery of 
cytotoxic agents resulted in enhanced drug accumulation in the tumor and tumor shrinkage. In 
dogs, device delivery resulted in large local drug concentrations and low systemic drug exposure. 
These devices have potential paradigm shifting implications for the treatment of pancreatic, 
breast, and other solid tumors.  
 iv 
 
 
 
 
ACKNOWLEDGEMENTS 
I would like to acknowledge all of the individuals who contributed to my work.  
Raheel Jajja was a fantastic colleague whose persistence and thoughtfulness enabled our 
success with both gemcitabine and FOLFIRINOX. Adrian O’Neill and Lissett Bickford 
assisted in the development of the implantable and transdermal devices, and their 
contributions were critical to the success of the project. Charlene Ross, the animal studies 
core, and the patient-derived xenograft core helped conduct many in vivo studies.   
I have been fortunate to have many great mentors.  My advisor, Joseph DeSimone, 
has provided me guidance in becoming an academician, entrepreneur, and family man, and 
he continually challenged me professionally and gave me phenomenal opportunities to grow 
as a scientist and engineer. Jen Jen has been a fantastic mentor, who constantly pushed me to 
ask the right questions, use evidence rather than theory to guide experimentation, and focus 
upon both the small details in my experimentation and presentation of my work. Joel Tepper 
provided significant guidance in my dissertation work and has been great support in my 
career aspirations. Leaf Huang taught me a great deal from my laboratory rotation, and he 
and Rudy Juliano have continued to provide significant mentorship as part of my dissertation 
committee. Mary Napier and Chris Luft have always been extremely supportive in the day-
to-day operations of the DeSimone lab.   
Finally, I would like to acknowledge my parents, Mike and Elaine, and wonderful 
fiancée, Maggie McGinn, for their continued support of my pursuits in science and medicine. 
 v 
 
 
 
 
TABLE OF CONTENTS 
Chapter 1 Introduction  ........................................................................................................................... 1 
1.1 Overview of Iontophoresis  .............................................................................................................. 1 
1.2 History of Iontophoresis ................................................................................................................... 2 
1.3 Iontophoretic Electrochemistry ........................................................................................................ 3 
1.4 Iontophoretic Transport Mechanisms ............................................................................................... 4 
1.5 Modern Iontophoretic Technologies ................................................................................................ 6 
1.5.1 Transdermal ................................................................................................................................... 7 
1.5.2 Transsceral ..................................................................................................................................... 7 
1.5.3 Intravesical .................................................................................................................................... 9 
1.5.4 Transmyocardial .......................................................................................................................... 11 
1.5.5 Intraductal .................................................................................................................................... 13 
1.5.6 Intraluminal ................................................................................................................................. 14 
1.6 Conclusion ...................................................................................................................................... 15 
1.7 References ...................................................................................................................................... 16 
Chapter 2 Local Iontophoretic Administration of Gemcitabine..…......……………...……………….26                               
for the Treatment of Pancreatic Cancer  
2.1 Overview ........................................................................................................................................ 26 
2.2 Introduction .................................................................................................................................... 26 
2.3 Results ............................................................................................................................................ 28 
2.3.1 Device Design and Proof-of-Concept Testing  ............................................................................ 28 
2.3.2 Drug Transport in Human Tissue ................................................................................................ 29 
2.3.3 Pharmacokinetic Studies in a PDX Pancreatic Cancer Model .................................................... 29 
2.3.4 Device Efficacy  .......................................................................................................................... 31 
2.3.5 PK in Dogs  ................................................................................................................................. 32 
2.4 Discussion  ..................................................................................................................................... 33 
2.5 Materials and Methods  .................................................................................................................. 35 
2.5.1 Design and Fabrication of Device  .............................................................................................. 35 
2.5.2 PDX Model of Pancreatic Cancer ............................................................................................... 35 
 vi 
 
2.5.3 Testing in Canine Model  ............................................................................................................ 36 
2.5.4 Processing of Tissue and Plasma  ................................................................................................ 37 
2.5.5 UV-High Performance Liquid Chromatography Assay .............................................................. 38   
2.5.6 Statistical Analysis  ..................................................................................................................... 39 
2.6 Additional Support  ........................................................................................................................ 39 
2.7 References ...................................................................................................................................... 40 
Chapter 3 Local Iontophoretic Administration of Cisplatin for the Treatment.…....…………………48                                
of Breast Cancer 
3.1 Overview……………………………………………………………………………………….....48 
3.2 Introduction .................................................................................................................................... 48 
3.3 Results ............................................................................................................................................ 50 
3.3.1 Device Development ................................................................................................................... 50 
3.3.2 Drug Transport in Human Tissue ................................................................................................ 51 
3.3.3 Pharmacokinetics and Biodistribution of Cisplatin ..................................................................... 51 
3.3.4 Device Efficacy ........................................................................................................................... 52 
3.4 Discussion  ..................................................................................................................................... 54 
3.5 Materials and Methods  .................................................................................................................. 55 
3.5.1 Device Fabrication ...................................................................................................................... 55 
3.5.2 Ex Vivo Studies  .......................................................................................................................... 56 
3.5.3 Animal Studies  ........................................................................................................................... 56 
3.5.4 PK Studies  .................................................................................................................................. 57 
3.5.5 Efficacy Studies ........................................................................................................................... 57 
3.5.6 PK and Statistical Analyses  ........................................................................................................ 58 
3.6 Additional Support  ........................................................................................................................ 59 
3.7 References ...................................................................................................................................... 60 
Chapter 4 Conclusions and Future Directions..………………………..……………………………...68                                       
4.1 References ...................................................................................................................................... 72 
 
 
 
 
 
 vii 
 
LIST OF EQUATIONS 
1.1 Total iontophoretic flux  ................................................................................................................. 22 
1.2 Electromigratory flux of an ion  ..................................................................................................... 22 
1.3 Electomigratory flux according to applied current and transport number  ..................................... 22 
1.4 Electomigratory flux of an ion in the presence of other charge carriers  ....................................... 22 
1.5 Current and volume flows resulting from the application of pressure and potential differences ... 22 
1.6 Electroosmotic flow as a function of volume and current flow ..................................................... 22 
1.7 Total iontophoretic flux of a cationic drug  .................................................................................... 22 
 
 
 
 x 
 
LIST OF FIGURES 
Figure 1.1. Model iontophoretic system. .............................................................................................. 20 
Figure 1.2. Different types of electrodes for iontophoretic drug delivery ............................................ 21 
Figure 1.3. Electrochemistry of commonly used electrodes................................................................. 23 
Figure 1.4. Relative ion flux as a function of molecular size ............................................................... 24 
Figure 1.5. Iontophoretic devices for local drug delivery .................................................................... 25 
Figure 2.1. Iontophoretic device for the delivery of gemcitabine ........................................................ 43 
Figure 2.2. Role of current on drug transport in ex vivo human tissue  ................................................ 44 
Figure 2.3. PK of device delivered gemcitabine .................................................................................. 45 
Figure 2.4. Therapeutic effect of gemcitabine delivered iontophoretically .......................................... 46 
Figure 2.5. Evaluation of single device treatments in a large animal model ........................................ 47 
Figure 3.1. Iontophoretic device for the delivery of cisplatin .............................................................. 63 
Figure 3.2. Role of current on drug transport in ex vivo human tissue  ................................................ 64 
Figure 3.3. PK of device delivered cisplatin ........................................................................................ 65 
Figure 3.4. Therapeutic effect of cisplatin delivered iontophoretically ................................................ 66 
Figure 3.5. Pharmacological evaluation of short-term renal toxicity ................................................... 67 
Figure 4.1. Iontophoretic devices for the treatment of solid tumors .................................................... 71 
 xi 
 
LIST OF ABBREVIATIONS 
Ag/AgCl – silver/silver chloride 
Pt - platinum 
F – Faraday’s constant 
A – cross-sectional area 
I - current 
tx – transport number of drug X 
ID – current density 
zx – charge of drug X 
ux – mobility of drug X 
cx – concentration of drug X 
Lii – Onsager coefficient 
pI – isoelectric point 
µL – microliter 
cm - centimeter 
h - hour 
µg – microgram 
mL - milliliter 
MMC – mitomycin C 
EMDA – electromotive drug administration 
PD – passive diffusion 
BCG – Bacillus Calmette-Guerin 
Cmax – maximum concentration 
 xii 
 
IV – intravenous 
mA – milliamperes 
g – gram 
µg – microgram 
VT – ventricular tachycardia 
TAT-59 – miproxifen phosphate 
DP-TAT-59 – dephosphorylated metabolite of miproxifen phosphate 
mm – millimeter 
wt% - weight percentage 
min – minute 
PEDOT – poly(3,4 – ethylenedioxythiophene) 
PDX – patient-derived xenograft 
UV – ultraviolet 
HPLC – high performance liquid chromatography 
PK – pharmacokinetics 
3D – three-dimensional 
kg – kilogram 
AUC – area under the curve 
NaCl – sodium chloride 
BUN – blood urea nitrogen 
FOLFIRINOX – Folinic acid, 5-fluorouracil, irinotecan, oxaliplatin 
THU – tetrahydrouridine 
IRB – Institutional review board 
 xiii 
 
IACUC – Institutional animal care and use committee 
M – molar 
v/w – volume/weight 
rpm – rotations per minute 
2’dC – 2’deoxycytidine 
mM – millimolar 
ng – nanogram 
Gy – gray 
ICP-MS – inductively coupled mass spectrometry 
ANOVA – analysis of variance 
SEM – standard error measurement 
NS – not significant 
 
 
 
 1 
 
 
 
 
CHAPTER 1: INTRODUCTION 
1.1 Overview of Iontophoresis 
As an electric field is generated across a conducting medium, a force is exerted on 
charged particles that exist within that medium. If the particles are able to move, the force 
results in an electric current. In metals, the force is exerted on conduction band electrons and 
the result is an electronic current. In ionic solutions, such as saline, the force is exerted on 
ions and the result is ionic current. 
Iontophoresis is a hybrid of these two currents established by an electric field. A 
power source is used to establish the electric field through an anode (positive electrode) and 
cathode (negative electrode) (Figure 1.1). The anode is at the highest potential and each 
successive point in this circuit is at a lower potential, and the cathode is the lowest potential 
point. The resulting electric fields cause electrons to migrate in the direction of the battery 
anode in the electronic portions of the circuit and causes ions to flow in the ionic solution 
portion of the circuit - positive ions moving toward the cathode and negative ions toward the 
anode. The ionic solution portion of the circuit is comprised of the anode reservoir, hydrated 
tissue between the anode and cathode reservoirs, and the cathode reservoir. The current 
flowing in the ionic parts of the circuit has two components: cations moving toward the 
cathode and anions moving toward the anode. If there are more than one species of cation or 
anion each species will contribute to the overall current depending on its concentration and 
mobility. At any surface drawn perpendicular to the direction of current flow, the total 
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number of ions passing through that surface per unit time must equal the current being 
delivered by the battery. 
If the solution of ions in the anode or cathode reservoir contains a therapeutic agent, 
then it will migrate in the direction of the opposite electrode and hence into the tissue. Thus, 
the applied electric field accomplishes drug delivery. Because of the ease with which the 
magnitude of the electric field can be changed, there are many advantages to this form of 
drug delivery [1]. 
 
1.2 History of Iontophoresis 
The first proposed use of an electric field for drug delivery dates back to the mid-18
th
 
century from Johann Gottlob Krueger [2]. Krueger stated that electricity should be “useful in 
medicine, as it was obviously not useful for theology or jurisprudence.” The first 
experimental evidence of the use of electric fields for drug delivery purposes was obtained in 
1747 by Giovanni Francesco Pivati [3]. Throughout the late nineteenth century, significant 
progress was made in the transdermal iontophoretic delivery of a variety of drugs, including 
atropine, quinine, lithium salts, and cocaine. In the 1930s, Elkin Percy Cumberbatch dictated 
the limitations of this method, which was principally the shallow depth ions are able to reach 
in tissues [4]. Cumberbatch and others proposed the application of ionic medication to organs 
other than the skin, including the urethra, middle ear, and cervix (Figure 1.2) [4-6]. Although 
these iontophoretic devices were generated for non-transdermal drug delivery, the 
predominant focus was on the transdermal application of iontophoresis.  
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1.3 Iontophoretic Electrochemistry 
There exist many different types of electrodes used in iontophoretic drug delivery. 
The two major types are classified according to their electrochemistry as reversible 
electrodes (silver/silver chloride (Ag/AgCl)) and inert electrodes (platinum) [7-9]. For 
Ag/AgCl electrodes, the electrochemistry occurring at the Ag anode requires the presence of 
Cl
-
 ions in the anodal compartment (Figure 1.3). Without the presence of the Cl
-
 ions, Ag
+
 
ions are transported with the drug. The requirement of the Cl
-
 ions can reduce the efficiency 
of drug delivery since highly mobile Na
+
 ions can compete very effectively with the drug to 
carry current; however, there are many water soluble drugs that are formulated as 
hydrochloride salts, which alleviates the need for the addition of NaCl. As the Cl
-
 ions arrive 
at the electrode–solution interface, they react with the metallic silver to form silver chloride, 
which on account of its low solubility product, is deposited at the electrode surface, 
simultaneously releasing an electron. In order to maintain electroneutrality in the anodal 
compartment, either a cation must move out of the compartment and into the tissue or an 
anion must leave the tissue and move into the anodal chamber. In the cathodal compartment, 
the AgCl is reduced by the arrival of electrons from the power supply and yields metallic 
silver together with a Cl
-
 ion, which passes into the solution, which must be compensated for 
by the arrival of a cation from within the tissue into the cathodal chamber or by the loss of an 
anion. One major advantage of Ag/AgCl electrodes is that the electrochemistry occurs at 
voltages lower than those necessary for the electrolysis of water. This is desirable since 
protons created at the anode of non-Ag/AgCl materials compete to carry charge and because 
of their small size and high mobility, they may significantly reduce drug delivery efficiency; 
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moreover, the low pH produced in the anodal compartment can lead to acid-induced burns, 
and it may have an adverse effect on drug stability.  
For Pt electrodes, the electrochemistry occurring at the Pt interface induces 
electrolysis during the release of electrons (Figure 1.3). This effectively reduces the pH 
around the electrode, which could severely impact the stability of the drug, drug delivery 
efficiency, and the integrity of the surrounding tissue depending upon the design of the 
electrode [10]. The advantage of Pt electrodes is that the electrode is relatively inert and does 
not breakdown in the same manner as Ag/AgCl electrodes.  
 
1.4 Iontophoretic Transport Mechanisms 
The observed iontophoretic flux of a charged species, X, at steady-state can be 
considered as the sum of two separate transport mechanisms – electromigration and 
electroosmosis, assuming that the passive permeability is negligible (Equation 1). 
Electromigration refers to the ordered movement of ions in the presence of the applied 
electric field. The electromigratory flux of an ion, X, is related to the component current flow 
ix due to its transport by Faraday’s constant, F, where A represents the cross-sectional area 
for transport across tissue and zx is the charge (Equation 2). The ionic current flow due to the 
movement of X can be related to the applied current, I, by a proportionality constant, tx, the 
transport number of X (0 < tx < 1), which describes the fraction of the total current 
transferred by X (Equation 3).  
 The transport number of X depends on the physicochemical properties of X and how 
these changes with the corresponding properties of the other charge carriers present in the 
system. Specifically, where ID is the applied current density ( = I/A) and zx, ux, and cx refer to 
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the charge, mobility and concentration of the drug in the membrane, respectively (Equation 
4); the denominator is the sum of the products of these parameters for each ion in the system 
contributing to charge transfer across the membrane. This form of the transport equation 
explains why the presence of competing ions can reduce the drug flux and delivery 
efficiency. Furthermore, the extent of competition and attenuation of drug transport will 
depend on the products of the respective electrical mobilities and concentrations in the 
membrane. Increasing the concentration of a less mobile drug species can improve delivery 
efficiency in the presence of a small highly mobile competing ion. 
The electroosmotic component is based upon non-equilibrium thermodynamics. Pikal 
has analyzed the phenomenon in considerable depth and elegantly described how the 
application of pressure and a potential difference across a membrane can be used to generate 
current and volume flows, respectively [11-14]. The two flow phenomena can be expressed 
as found in Equation 5.  
The flows are related to their causal or conjugate forces, by the respective Onsager 
coefficients, Lii; L11 gives the volume flow in response to the application of a pressure 
gradient and L22 is the proportionality constant relating the potential difference to the current. 
The cross coefficients Lij describe interaction terms. Thus, L12 defines how application of a 
potential difference across a membrane will create a volume flow. In an iontophoretic 
experiment when an electric field is applied across the tissue, ΔPressure = 0, electroosmotic 
flow is equivalent to volume flow divided by current flow (Equation 6). 
Electroosmosis can be explained as the volume flow induced by the current flow. At a 
molecular level, electroosmosis can be viewed as resulting from the fact that the tissue has an 
isoelectric point (pI) ~ 4–4.5 [15], above which the carboxylate groups present in the 
 6 
 
membrane become ionized. Application of an electric field across a charged membrane 
favors the movement of counter-ions that try to neutralize the membrane charge and gives 
rise to its cation permselectivity. Electroosmosis can be defined either as a flow process that 
is volume flow per unit area per unit time or as a solvent velocity, v, and it is equivalent to a 
permeability coefficient with corresponding units. The existence of this solvent flow in the 
anode-to-cathode direction means that (i) neutral molecules can be delivered by anodal 
iontophoresis and (ii) cations will benefit from a second driving force in addition to 
electromigration. The total flux of X, a cationic drug, is shown in Equation 7.  
From these equations, it would appear that iontophoretic flux should increase with 
drug concentration and with applied current; the patch area can also be enlarged to further 
increase the amount of drug delivered. The relative importance of electromigration and 
electroosmosis to the total flux of a molecule depends on its physicochemical properties. 
Electrical mobility will decrease with molecular weight and the electroosmotic contribution 
is increasingly important for larger molecules (Figure 1.4) [16]. 
 
1.5 Modern Iontophoretic Technologies 
Many researchers have utilized iontophoretic drug delivery systems to increase 
locoregional drug concentrations while abating toxic systemic side effects associated with 
current intravenous, oral, and passive administrations. Numerous device studies have been 
conducted for the local and systemic delivery of drugs by iontophoresis through skin, non-
muscle invasive bladder tumors, ocular tissue, restenotic vessels, and myocardial tissue. A 
number of the delivery systems have gained regulatory approval from the United States Food 
and Drug Administration and the European Medicines Agency [17].  
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1.5.1 Transdermal 
Transdermal drug delivery has been the most well-studied application within the field 
of iontophoresis, and there have been a plethora of transdermal iontophoretic devices for the 
local and systemic delivery of drugs. Prime examples include devices that have been 
developed for delivering lidocaine to promote local anesthesia (LidoSite®) seen in Figure 
1.5, administering fentanyl to treat systemic pain (Ionsys™), and monitoring glucose levels 
in diabetics (GlucoWatch Biographer™) [17]. Overall, there are hundreds of examples of 
transdermal iontophoretic drug delivery studies in the literature and many associated patents 
filed for these iontophoretic devices [18]. 
 
1.5.2 Transscleral 
Ocular iontophoresis addresses the issues of low bioavailability of drugs after topical 
administration and the complexities of intraocular injections [19]. Due to the ease and safe 
delivery of drugs by ocular iontophoresis, clinical use of this treatment has become more 
extensive, resulting in technologies that improve drug delivery to the eye.  
Numerous studies have been conducted that have shown that the penetration and 
retention of drugs in the eye through iontophoresis is greater than that of standard topical and 
subconjunctival administrations [19]. Grossman et al. conducted an analysis of the delivery 
of gentamicin to the anterior cornea, aqueous humor and vitreous in rabbits, comparing a 
subconjunctival injection to transscleral and transcorneal iontophoresis [20]. After 2 hours, 
the gentamicin delivered by transcorneal iontophoresis peaked in the cornea at 376.1 g/ml 
and reached an average level of only 28.1 g/ml by subconjunctival administration. The Cmax 
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of transcorneal iontophoretic penetration in the aqueous humor was 54.8 g/ml, which was 4 
times higher than the peak drug penetration from subconjunctival injection. The Cmax of 
transscleral iontophoretic gemtamicin levels in the vitreous was 20 times higher than drug 
levels produced by subconjunctival drug administration. Ocular iontophoretic studies have 
evaluated the delivery of antibiotics, antiviral drugs, antifungal drugs, steroids, and 
oligonucleotides. This emerging ophthalmic treatment provides an innocuous way to deliver 
drugs, eliminating the poor drug delivery to posterior portions of the eye seen with topical 
administrations and the complexities and pain associated with subconjunctival injections. 
The novel field of nanoparticle delivery is offering another method of ophthalmic 
drug delivery when used in conjunction with ocular iontophoresis. Studies by Eljarrat-
Binstock et al. examined the transport of positively and negatively charged particle delivery 
by electrophoresis compared to nanoparticle delivery by passive diffusion [21]. Hydrogel 
reservoirs filled particle suspensiosn were placed directly on the eye; three groups received 
positively charged particles through cathodal electrophoresis, one group acquired negatively 
charged particles through anodal electrophoresis, and two groups received either positively or 
negatively charged particles through passive diffusion. Through studies in rabbits, large 
particles concentrations were observed in the eye due to electrophoretic transport, though 
positively charged particles exhibited higher penetration into ocular tissues than did 
negatively charged particles. Moreover, nanoparticles could be of particular benefit through 
controlled drug release into tissues, possibly providing an answer for the delivery of non-
ionized drugs or drugs with high molecular weights and poor ocular tissue penetration
 
[21].  
Ocular iontophoretic devices are now being manufactured by companies including 
Eyegate, Visulex and OcuPhor. The devices typically consist of eye cups and drug-
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loaded hydrogels to deliver drugs by iontophoresis. Eye cups are composed of a port that 
delivers the drug, and a metal electrode that controls the current supply and aspirates bubbles 
to keep the eye cup in place (Figure 1.5B). There is a reservoir located in the cup that 
continuously imbues the drug solution into the eye, allowing for a controlled and localized 
delivery
 
[19]. Hydrogel applicators have been fabricated by Visulex and OcuPhor to 
optimize ocular drug delivery. The OcuPhor hydrogel consists of a drug saturated gel that 
is placed into a reservoir and a metal electrode, which allows for a mild current to transport 
drugs through the eye. Visulex has expanded upon this ocular iontophoretic hydrogel 
model by creating a selective membrane that increases the mobility of drug molecules across 
ophthalmic tissues by limiting non-drug current carrying ion transport [19]. Eyegate has 
created transscleral iontophoretic delivery systems that have enabled the application of drugs 
to the anterior and posterior chambers of the eye
 
[22]. New manufactured ocular 
iontophoretic devices are enhancing the delivery of drugs, allowing for a safer and more 
effective method of treatment for ophthalmic diseases. 
 
1.5.3 Intravesical 
Intravesical delivery of mitomycin-C (MMC) to non-muscle invasive bladder cancer 
has been the source of a myriad of studies aimed to enhance the efficacy of local drug 
delivery to tumors. Electromotive drug delivery (EMDA), also known as iontophoresis, 
offers a way to increase localized drug delivery to tumors, eliminate systemic side effects and 
lengthen remission rates and disease-free intervals [23]. 
Electromotive drug administration has led to increased efficacy of MMC delivery 
compared to the standard therapy of passive diffusion (PD) to treat bladder malignancies. Di 
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Stasi et al.
 
examined the penetration of MMC in the urothelium ex vivo, comparing the 
efficacy of PD and EMDA delivery [24-25]. The electromotive administration resulted in 
increased local MMC delivery and penetration compared to PD; a four-fold to seven-fold 
increase in the rates of EMDA delivery of MMC was observed
 
[24]. In a patient study by 
Rieldl et al., transurethral resection was followed by intravesical delivery of MMC by 
EMDA [26]. After 14.1 months, 9 of the 16 patients were free of recurrent bladder cancer, 
and systemic side effects that are associated with standard MMC drug administration did not 
occur. Clinical studies comparing PD and EMDA of MMC are few, but the studies that have 
been conducted have resulted in better efficacy for patient’s treated by EMDA compared to 
PD.  
Data has suggested that the transport of MMC by EMDA is an alternative to or at 
least equivalent in effectiveness to the standard Bacillus Calmette-Guerin (BCG) treatment of 
care, which stimulates an immune response in the bladder to destroy malignant cells [27]. Di 
Stasi et al. conducted a randomized study to evaluate the efficacy of EMDA/MMC, BCG, 
and PD [28]. One hundred and eight patients received a 6 week treatment; three groups 
received either one instillation of 40 milligrams (mg) MMC by PD, a single 30 minute 
EDMA delivery of 40 mg of MMC under a current of 20 mA, or 2 BCG instillations of 81 
mg. The efficacy of EDMA/MMC and BCG treatments was greater than PD, but there was 
little difference between EMDA and BCG, which suggests that EDMA could possibly be 
used as an alternative to BCG in treating bladder cancer [29]. The plasma concentrations of 
MMC by EMDA reached a Cmax that was 5.5 times greater than PD of MMC, concluding that 
the efficacy of transmembranous drug transport is enhanced by localized electromotive 
delivery.  
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When BCG and EDMA/MMC are used in conjunction, there is an enhancement in 
effect compared to only BCG or EMDA/MMC treatments
 
[27].  In a study by Di Stasi et al., 
patients were treated with BCG and EMDA/MMC sequentially, testing the hypothesis that 
the convergence of two therapies could act synergistically, improving the overall therapeutic 
efficacy. The studies proved that patients who received BCG and EMDA/MMC sequentially 
had a longer disease-free interval than patients who only received BCG. All 78 of stage T1 
patients who received both therapies did not see a recurrence of disease after 3 months 
compared to the recurrence of bladder cancer in 3 of the 75 patients who received only BCG. 
After 88 months, 106 of the patients were disease-free: 41.9% received only BCG and 57.9% 
received sequential deliveries of BCG and EDMA/MMC. During a follow up, 23 deaths due 
to bladder cancer occurred: 17 in the BCG group and 6 in the BCG and EDMA/MMC group. 
Side effects were localized in the bladder and the toxicity of both treatments was very 
similar. The results of the Di Stasi studies led to the conclusion that sequential delivery of 
BCG and EDMA/MMC can increase survival and disease-free intervals [27].   
 
1.5.4 Transmyocardial 
The adverse systemic side effects associated with current drug administration to treat 
arrhythmias have prompted the development of novel iontophoretic devices to deliver drugs 
locally to cardiac tissues [30]. Transmyocardial iontophoretic drug delivery offers a way to 
increase drug penetration, effectively targeting the affected tissues. 
Studies have evaluated the efficacy of iontophoretic drug delivery to the myocardium 
compared to that of standard-of-care approaches. In a study by Avitall B et al., procainamide 
was delivered via iontophoresis to canine models through an implantable defibrillator patch 
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electrode (9 mA), passive diffusion (PD), and intravenous (IV) administration for a ten 
minute delivery period [30]. Procainamide concentrations in the epicardial layer were 840 
g/g, 93 g/g and 15 g/g 3 hours after iontophoretic, PD and IV administrations, 
respectively. IV doses used were 15 mg/kg followed by 0.6 mg/kg/min for 3 hours, which 
was similar to human dosing. Iontophoretic drug delivery resulted in lower levels of 
procainamide in the blood (2  3 g/g) compared to intravenous levels (11  7 g/g), though 
passive diffusion resulted in the lowest systemic drug levels (1  1 g/g). In all canine 
models that received iontophoretic procainamide delivery, ventricular tachycardia (VT) was 
rapidly suppressed and sustained for 60 minutes, and in 7 of 10 dogs, VT was suppressed for 
3 hours. The effective refractory period and the diastolic threshold did not significantly 
increase due to iontophoretic procainamide delivery. In another canine study by Labhasetwar 
et al., a heterogenous cation-exchange membrane was used in the iontophoretic transport of 
dl-sotalol hydrochloride from an epicardial reservoir sutured onto the myocardium [31]. The 
study determined that the release rate of the drug from the device was linearly correlated with 
the current applied, and peak coronary sotalol levels positively correlated with the applied 
current.  
Though local iontophoretic drug transport directly to the myocardium improves 
delivery efficacy due to the low resistance of cardiac tissues, there is still potential for 
optimizing devices and transport. Parameters, including drug concentration, drug type, 
duration of drug transport, and electrode size and configuration, still needs to be evaluated to 
determine optimal delivery [30]. Overall, transmyocardial iontophoretic drug delivery was 
proven to be a more effective drug delivery technique than passive diffusion and IV 
administration.   
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1.5.5 Intraductal 
Intraductal drug administration using iontophoresis offers a novel method to locally 
deliver chemotherapies to ductal carcinomas [32-33]. Komuro et al.
 
developed an 
iontophoretic device that delivered the antiestrogen drug, miproxifen phosphate (TAT-59), 
and the active metabolite of TAT-59, dephosphorylated metabolite miproxifen (DP-TAT-59) 
through the nipple, directly into the mammary ducts. In in vitro rat skin studies, iontophoretic 
drug delivery, using 0.5 mA/cm
2
 for two hours, was compared to passive diffusion. Using 
high performance liquid chromatography, TAT-59 concentrations were determined, 
affirming that iontophoretic delivery increased drug permeation into the ducts compared to 
passive diffusion, where TAT-59 penetration was hardly detectable. In a canine in vivo study 
by Komuro et al., iontophoretic delivery was compared to oral administration [32]. TAT-59 
tissue concentrations were compared after 5 days of repeated iontophoretic delivery and 14 
days after oral delivery, when the drug reached a steady state. The studies indicated that 
TAT-59 was delivered directly to the mammary tissues after iontophoretic delivery and TAT-
59 drug levels were undetectable in the plasma. The area under the curve value of DP-TAT-
59 was 3 times larger during iontophoresis than oral administration, indicating an increase in 
DP-TAT-59 delivery due to iontophoretic administration.  
Iontophoretic devices to treat ductal carcinoma offer non-invasive routes of drug 
delivery that can be self-administered by patients. One drawback is that drug concentration 
within the tissues tends to vary between patients due to the biological and physiological 
differences [32]. Though the drug concentration still needs to be optimized, iontophoresis has 
the potential of increasing the efficacy of drug delivery to mammary ducts and tissues.  
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1.5.6 Intraluminal 
The inefficiency of current percutaneous therapies for treating restenosis has led to 
the fabrication of an iontophoretic balloon to transport anti-restenotic drugs to vessel walls 
after angioplasty
 
[34]. A balloon catheter consisting of an Ag/AgCl cathodal electrode 
wrapped around a catheter shaft and an anodal electrode placed on the skin was developed by 
CorTrak Medical, Inc,. The catheter was surrounded by a porous balloon with impermeable 
ends that is placed in contact with the vessel walls, allowing for increased localized drug 
delivery [35-37].  
Studies have been conducted with the intention of optimizing anti-restenotic agent 
delivery to narrowed blood vessels, testing the pharmacokinetics and localization of coronary 
delivery
 
[38]. Fernandez-Ortiz et al. conducted an in vivo study using an iontophoretic 
catheter to deliver 
125
I-hirudin throughout the layers of the arterial wall [34]. In the porcine 
study, r-hirudin was transported to 20 arteries, 2 by means of passive diffusion and 18 by a 4 
mA/cm
2
 current density for 5 minutes. Drug levels due to the iontophoretic balloon catheter 
were 80 times higher than r-hirudin levels by passive diffusion. The drug levels in vessels 
declined rapidly, decreasing from a Cmax of 0.78 g g tissue
-1
 mm
-1
 by iontophoretic delivery 
to 0.14 g g tissue-1 mm-1 after 1 hour and 0.02 g g tissue-1 mm-1 after 3 hours. The vessels 
that received the drug through iontophoretic balloon catheter administration suffered only 
minimal damage by the device 48 hours after treatment. In another in vivo study conducted 
by Mitchel et al., intravascular iontophoretic balloon catheters delivered heparin into the 
coronary arterial walls of 33 rats and 21 pigs [33]. Iontophoretic delivery in the rat studies 
delivered 13 times the levels of heparin than that of passive diffusion. In a study by Robinson 
et al., oligonucleotides were delivered to coronary arteries in pigs after angioplasty; there 
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was a detectable amount of the delivered oligonucleotide distributed throughout the arterial 
tissue that persisted for 7 days [38]. In a study by Markwart F et al., iontophoretically 
delivered dextran-bound hirudin displayed a tissue half-life of 7 hours compared to the short 
tissue half-life of r-hirudin (1-2 hours) [34,39]. Liposomes and microspheres are also under 
investigation for increasing the duration of drug levels, offering a possibility of delivering 
larger dosages of drugs at controlled rates [37]. Iontophoretic balloon catheters provide a 
non-invasive way to directly target angioplasty sites, delivering increased concentrations of 
anti-restenoic drugs, oligonucleotides, hirudin, and heparin into blood vessels.  
 
1.6 Conclusion 
The overview of iontophoretic drug delivery presented here illustrates that a 
considerable amount of effort has gone into exploring the feasibility of iontophoresis as a 
treatment platform for a number of therapeutic areas and many different drug molecules with 
diverse physicochemical properties. Overall, iontophoresis confers control over the drug 
input kinetics and the ability to customize drug input rates that can be optimized for a given 
patient.  
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Figure 1.1. Model iontophoretic system involving a power source connected to two 
electrodes generating an electric current in a cationic drug solution.   
 
 
 
 
 
 
 
 21 
 
 
Figure 1.2. Different types of electrodes for iontophoretic drug delivery. (A) Diffusion 
electrode according to Adamkiewicz, (B) electrode for urethral iontophoresis, (C) electrode 
according to Franklyn for treating hay fever by zinc ionization, (D) vulcanite funnel electrode 
for ionization of the mucous membrane of the middle ear, (E) zinc rod electrode used for 
ionization of the mucous membrane of canal or cervix uteri [4-6]. 
 
 
 
 
 
 
 
 
 
A B 
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Inert electrodes: e.g., carbon or platinum electrodes 
2 H2O      4H
+ + O2 + 4 e
– (at anode) 
2 H2O + 2 e
–       H2 + 2HO
– (at cathode) 
 
Reversible electode: e.g., Ag/AgCl electrodes 
Ag       Ag+ + e–      AgCl + e– (at anode)  
AgCl + e–      Ag + Cl– (at cathode) 
 
Figure 1.3. Electrochemistry of commonly used electrodes for iontophoretic drug delivery. 
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Equation 1.1. Total iontophoretic flux. 
 
Equation 1.2. Electromigratory flux of an ion, X, is related to the component current flow iX 
due to its transport by Faraday’s constant, F. 
 
Equation 1.3. Electomigratory flux according to applied current, I, and a proportionality 
constant, tX. 
 
Equation 1.4. Electomigratory flux of ion X in the presence of other charge carriers. 
 
Equation 1.5. Current and volume flows resulting from the application of pressure and 
potential differences across a membrane.   
 
Equation 1.6. Electroosmotic flow is the result of volume flow induced by the current flow. 
 
Equation 1.7. Total iontophoretic flux of a cationic drug. 
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Figure 1.4. Relative ion flux as a function of molecular size [16]. 
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Figure 1.5. Iontophoretic devices for local drug delivery. (A) Lidosite for the transdermal 
delivery of lidocaine [10]. (B) Eyegate II delivery system for ocular iontophoresis to the 
anterior and posterior of the eye [22]. (C) EMDA device used to locally deliver MMC to 
bladder cancer [23]. (D) Transmyocardial iontophoretic device for delivery of anti-
arrhythmic drugs [30]. (E) Intraductal delivery of an anti-estrogen drug for ductal carcinomas 
in situ [32]. (F) Coronary artery iontophoretic balloon catheter for delivery of anti-restenotic 
drugs [37]. 
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CHAPTER 2: LOCAL IONTOPHORETIC ADMINISTRATION OF GEMCITABINE 
FOR THE TREATMENT OF PANCREATIC CANCER  
 
2.1 Overview 
With an incidence rate approximately equivalent to the death rate, pancreatic cancer 
is the fourth leading cause of cancer death in the United States. The poor prognosis is in part 
attributed to the ineffective delivery of chemotherapeutics. Poor tissue perfusion plays a 
substantial role in preventing adequate drug accumulation in primary pancreatic tumors. In 
an attempt to address the ineffectiveness of systemically administered gemcitabine, we have 
developed modalities for the localized delivery of cytotoxic chemotherapies to pancreatic 
tumors. These devices utilize an applied electric field to drive chemotherapeutics into the 
tumor. Device treatments were performed in patient-derived xenograft mouse models of 
pancreatic cancer and a non-tumor bearing canine model. We demonstrate that local 
iontophoretic delivery of gemcitabine results in enhanced drug accumulation, penetration, 
and efficacy compared to IV administration. 
 
2.2  Introduction 
In 2014, it is estimated that 46,420 new cases of pancreatic cancer will be diagnosed 
and 39,590 individuals will die from pancreatic cancer in the United States. The 1-year and 
5-year relative survival rates for all stages are 24% and 5%, respectively [1,2]. Surgical 
resection offers the only cure, but only 20% of patients have resectable disease at the time of 
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diagnosis. Approximately 40% of patients have metastatic disease and another 40% have 
locally advanced unresectable tumors [3].  
Systemic control of pancreatic cancer has been the primary emphasis in research 
efforts, yet local control rates of this disease remain poor. Local symptoms of pancreatic 
tumors can cause substantial morbidity and decreased quality of life, suggesting a dire need 
for an adjunct to surgery and palliative care of this devastating cancer. Systemically delivered 
gemcitabine and other chemotherapies have been suggested to be ineffective in the local 
control of pancreatic cancer because of impaired drug delivery [4]. Poor tissue perfusion 
plays a substantial role in preventing adequate drug exposure to primary pancreatic tumors 
[4-9]. For this reason, we have proposed to employ an iontophoretic approach to drive 
increased amounts of chemotherapeutics deep into the primary tumor [10]. In the area of 
oncology, iontophoretic techniques have been successfully translated to the treatment of 
bladder cancers in the delivery of mitomycin C [10-12].  
Herein, we describe the first iontophoretic device for the local delivery of a cytotoxic 
chemotherapy to pancreatic tumors. This use of an applied electric potential for local delivery 
of chemotherapies offers the capability of overcoming the considerable flow and pressure 
gradients seen in pancreatic tumors. Overall, this device potentially offers an entirely new 
modality for the treatment of pancreatic cancer under the emerging field of interventional 
oncology. Moreover, the further development of these devices could translate directly into 
new treatments for other types of primary tumors and metastatic diseases.   
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2.3 Results  
2.3.1 Device Design and Proof-of-Concept Testing 
Our devices were designed to adapt conventional iontophoretic drug delivery 
techniques. Figure 2.1A-C showcases the device, the assembly, and the setup for animal 
treatments. The devices primarily consisted of (i) an electrode in direct contact with the drug 
solution, (ii) a polyurethane reservoir surrounding the electrode, and (iii) an inlet and outlet 
for continuous drug flow through the reservoir. This continuous drug flow maintained a 
constant drug concentration around the electrode and pressure within the device. Under an 
applied electric potential, the drug was transported in the direction normal to the electrode 
and into the tissue. 
A number of device parameters were evaluated to determine the optimal drug 
transport conditions from the device, including drug influx rates (Figure 2.1D), electrode 
material (Figure 2.1E), currents applied (Figure 2.1F), and drug concentration (Figure 2.1G). 
We found that drug influx at 50 µL/min or greater resulted in the largest amount of 
gemcitabine delivered into tissue surrogates (2 wt% agarose gels) at 2 mA while maintaining 
a low voltage (P = 0.006) (Figure 2.1D). Two mA was the maximum current allowed without 
impacting the integrity of the device. A number of conducting materials with diverse 
electrochemical properties for the device anode were evaluated, including platinum, silver, 
and poly(3,4-ethylenedioxythiophene) (PEDOT). We found that silver was the most efficient 
material for drug transport into tissue surrogates (P = 0.03) (Figure 2.1E). However, the 
electrochemical reaction at the silver anode interface prohibited its long-term use due to the 
buildup of silver chloride. Platinum was chosen for long-term implanted device studies, 
while silver was used for short-term non-implanted device studies. The application of 2 mA 
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of current resulted in 1.44-fold greater drug transport compared to 1 mA of current (P = 
0.056) (Figure 2.1F). Lastly, the transport of three concentrations of gemcitabine, 40, 20, and 
10 mg/mL, into tissue surrogates using a 2 mA constant current applied for 10 minutes 
resulted in significantly large differences in drug transport (P = 0.0001 for 40 vs 20 mg/L 
gemcitabine and P = 0.0004 for 20 vs 10 mg/mL gemcitabine) (Figure 2.1G). In addition to 
optimizing device functionality, testing these parameters on tissue surrogates gave us a 
preliminary idea of the drug transport capability. 
 
2.3.2 Drug Transport in Human Tissue 
Ex vivo drug transport studies were conducted using pancreatic cancer patient-
derived xenografts (PDXs). To test the transport of gemcitabine in the ex vivo PDX tumors, 
the devices were sutured onto the tumors and the counter electrode placed on the 
contralateral side of the tumor. Two or 0 mA of current was applied for 10 minutes, and the 
tumors were subsequently snap frozen, processed, and analyzed by UV-high performance 
liquid chromatography (HPLC). The application of current resulted in a 9.1-fold increase in 
drug transport when current was applied compared to the passive diffusion control (current = 
0 mA) (Figure 2.2). 
 
2.3.3 Pharmacokinetic Studies in a PDX Pancreatic Cancer Model 
Iontophoretic delivery of gemcitabine was further characterized with respect to 
pharmacokinetics (PK) in an orthotopic PDX model of pancreatic cancer. Recent reports in 
lung, pancreatic, breast and colon cancers, as well as glioblastomas, suggest that patient 
tumors directly implanted in immune-compromised mice exhibit response rates to cytotoxic 
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or targeted therapies more similar to patient responses [13-16]. These tumors retain the 
heterogeneity and histological characteristics of the original patient tumors. In the PDX 
model, devices were surgically implanted when the tumor reached a median size of ~260 
mm
3
, as determined by high-resolution 3D ultrasound that correlated very well with volume 
displacement.  Mice were allowed to recover for a week after device implantation. A single 
treatment was administered and tumors were harvested at designated time points. Figure 2.3 
shows a typical PK study for the device delivery of gemcitabine compared to IV delivery (80 
mg/kg). Gemcitabine plasma exposure as measured by the area under the curve (AUC) for IV 
delivery was 65.2 hr*µg/mL, with no detectable gemcitabine in the plasma of the device arm. 
Furthermore, gemcitabine tumor AUC for iontophoretic delivery and IV delivery were 384.1 
and 30.8 hr*µg/g, respectively. The average distances that gemcitabine was detected in the 
tumors in the direction away from the devices were 4.7 mm at 0 hours and 3 mm at 3 and 6 
hours; for IV gemcitabine-treated mice, gemcitabine was detected throughout the entirety of 
the tumor but at significantly lower drug concentrations. Additionally, single time point PK 
of the device delivery of high (40 mg/mL) or low (10 mg/mL) gemcitabine concentrations 
(n=3, each) was evaluated directly after treatment revealing 11.6-fold and 2.4-fold higher 
amounts of gemcitabine in the tumor and significantly lower plasma exposure compared to 
IV delivery. The average distances that gemcitabine was detected in the tumors in the 
direction away from the devices were 5.0 mm for the high gemcitabine concentration and 3.7 
mm for low gemcitabine concentration. We observed that the drug accumulation in the tumor 
and distance of drug transport was dependent upon the influx gemcitabine concentration, 
which correlated with the in vitro drug transport results. 
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2.3.4 Device Efficacy 
To evaluate the antitumor activity of gemcitabine delivered by the iontophoretic 
devices, we performed efficacy studies in an orthotopic PDX pancreatic cancer model. 
Devices were surgically implanted onto orthotopic PDX tumors when their size reached ~260 
mm
3
, as determined by high-resolution 3D ultrasound. Mice were treated twice a week for up 
to 7 weeks with device gemcitabine (20 mg/mL), device saline (0.9% NaCl), IV gemcitabine 
(80 mg/kg), or IV saline. Implanted devices impaired ultrasound imaging, and thus, tumor 
volumes were measured by volume displacement only after completion of the scheduled 
treatment. Device gemcitabine resulted in significant tumor regression in 7 of 7 mice, 
outperforming IV gemcitabine and the control arms of IV and device saline over the 52-day 
period of the study (Figure 2.4). Mice treated with device gemcitabine had a mean log2-fold 
change in tumor volume of -0.8 compared to a mean log2-fold change in tumor volume of 1.1 
for IV gemcitabine (P < 0.0001), 3.0 for IV saline (P < 0.0001), and 2.6 for device saline 
groups (P < 0.0001). Mice treated with device saline had tumor volumes that were not 
statistically different from mice treated with IV saline. Device gemcitabine was better 
tolerated based on greater body weight gain compared to IV gemcitabine with minimal 
changes in alanine transaminase, aspartate transaminase, blood urea nitrogen (BUN), and 
lipase. Overall, device gemcitabine resulted in tumor regression in 7/7 mice compared to no 
regression (0/7) in the IV gemcitabine group while maintaining low systemic exposure of 
gemcitabine. Histological samples from the tumors post-treatment revealed a decrease in 
stain for a marker of cell proliferation, Ki-67, from device gemcitabine-treated mice 
compared with tumors from mice that received IV gemcitabine, IV saline, or device saline. 
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2.3.5 PK in Dogs 
To further evaluate the implantable iontophoretic device, a representative large 
animal model for humans was used. However, since there was no readily available large 
animal model for pancreatic cancer, a non-tumor bearing canine model was chosen. A 
laparotomy was performed to expose the pancreas, and devices (Figure 2.5A) were sutured 
directly onto the pancreas. A constant current of 10 mA was applied for 60 minutes using 
either 40 or 10 mg/mL gemcitabine (n = 5 per group). For the IV treatment arm (n = 4, per 
group), clinical protocol was followed for gemcitabine administration, which was an infusion 
of a 1 g/m
2
 dose for 30 minutes, and the animal was euthanized 60 minutes after the start of 
the infusion. The plasma was sampled at 15 minute increments before, during, and after 
therapy (Figure 2.5B). After therapy, the tissues were subsequently removed, flash-frozen, 
and analyzed by UV-HPLC. There was no drug detected in the plasma of the animals at any 
time when a low gemcitabine concentration (10 mg/mL) was used in the device treatment. In 
the plasma of dogs treated with the high gemcitabine concentration (40 mg/mL) delivered by 
the device, 2 of 5 dogs had detectable levels of gemcitabine, but the levels of gemcitabine 
detected were at least 25-fold less than the IV treatment (p < 0.0001). Gemcitabine was 
detected in the plasma of all dogs that received IV gemcitabine. There was a 7.1- and 2.0-
fold increase in the concentration of gemcitabine in the normal canine pancreas after device 
delivery using high (p = 0.0002) and low (p = 0.42) gemcitabine concentrations, respectively, 
compared to IV administration (Figure 2.5C). The distance of gemcitabine transport after 
device treatment using high and low gemcitabine concentrations were statistically different 
(p = 0.03) at 9.6 mm and 6.3 mm away from the electrode, respectively (Figure 2.6D). 
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2.4 Discussion  
Novel therapeutic strategies, such as local drug delivery devices, are critical for the 
improvement of pancreatic cancer treatments. Local delivery of chemotherapeutic agents 
allows for an increase in the concentration of the drug in the area of greatest need, while 
limiting systemic side effects of IV and orally administered chemotherapeutic agents. 
However, relatively few methods have been developed for the local delivery of 
chemotherapeutic agents for pancreatic cancer. Tanaka and colleagues have generated a 
method for the temporary unification of the pancreatic blood supply for advanced pancreatic 
cancer, which enhances regional drug delivery into the pancreas and liver [17]. Furthermore, 
interventional endoscopic ultrasound enables the use of radiofrequency ablation and injection 
of anti-cancer agents, such as ONYX-015 and TNFerade™ [18].  
The results from our in vivo device studies suggest the opportunity for improved and 
effective local delivery of gemcitabine and other cytotoxic therapies for the treatment of 
pancreatic cancer. Gemcitabine has a short half-life in the systemic circulation of humans, 
which is similar to the canine model where gemcitabine has a half-life of 1.38 hours [19]. 
The rapid metabolism of gemcitabine in the plasma can be overcome by local drug delivery. 
Our data indicate that significant amounts of gemcitabine can be transported in the local 
region surrounding the devices when a constant current is applied. Systemic exposure after 
device delivery is extremely low, and in many of our studies, not quantifiable. Furthermore, 
the device configurations that were evaluated prove the use of a clinically relevant electrode 
system for the iontophoretic delivery of gemcitabine.  
Currently, the only cure for pancreatic cancer is resection of the primary tumor 
lesions. Approximately 80% of patients are considered ineligible for surgical resection 
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because the tumor has either invaded critical vessels or metastasized to more distant organs 
[20]. Our device has the potential to be a neoadjuvant therapy that may help convert the 40% 
of patients with tumors that are unresectable but not metastatic to surgical candidates. The 
device’s ability to increase intratumoral drug concentrations well above current methods of 
drug administration, while maintaining low systemic exposure, can increase rates of tumor 
regression and margin-negative surgical resection. For patients with metastatic disease and 
debilitating local symptoms such as pancreaticobiliary and gastric outlet obstruction, this 
device can provide a palliative modality to improve symptom control. Moreover, this therapy 
could be used as an adjunct treatment to systemically administered therapy, in order to treat 
primary and metastatic tumors lesions. One tremendous advantage would be to leverage our 
device for the delivery of agents that are limited by systemic toxicity. For example, 
FOLFIRINOX is a promising cytotoxic combination but with limited utility in many patients 
due to its high level of systemic toxicity [21]. Therefore, device delivery of FOLFIRINOX 
would have the potential to substantially improve the resectability and local control rate in 
patients with locally advanced and unresectable pancreatic cancer. 
Our devices could potentially offer entirely new modalities for the treatment of 
pancreatic cancer under the emerging field of interventional oncology. We further anticipate 
this being a platform technology that will translate directly into the treatment of other cancers 
including the chest recurrence of breast cancer and head and neck, esophageal, and colorectal 
cancers. 
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2.5 Materials and Methods 
2.5.1 Design and Fabrication of Device 
Iterative device design was performed using the 3D computer-aided design software, 
SolidWorks. The devices were fabricated according to a reservoir-based design. For the 
murine device, a polyurethane reservoir was fabricated with a stainless steel wire ring 
embedded to allow for suturing of the device to the tumor. A platinum disc was soldered to a 
stainless steel cable wire and embedded in the reservoir. The electrode wire was threaded 
through the multi-luminal tubing. A semipermeable cellulose membrane was adhered to the 
casing to enclose the reservoir. For the canine device, a polyethylene reservoir was 
fabricated, and one side of a 1 cm silver circular electrode was soldered to an insulated 
copper conducting wire. Press-molding was used to attach a semi-permeable cellulose 
membrane, which was situated parallel to the silver electrode to allow for drug transport into 
the tissue from the reservoir. A dual luminal tube was inserted into the reservoir for drug 
flow into and out of the reservoir. A nylon mesh was adhered by Dymax UV cure adhesive to 
the back of the pressurized anode. For the cathode on the back of the murine model, a 1 cm 
silver chloride disc was used. For the cathode on the back of the canine model, a 5x7 inch 
electrocautery plate was used.  
 
2.5.2 PDX Model of Pancreatic Cancer 
Under IRB approval and according to IACUC guidelines, de-identified tumors of 
pancreatic cancer patients were grafted and passaged into immunocompromised mice as 
previously described [22]. Devices were surgically implanted on to the subcutaneous flank 
tumor once tumors reached an average size of 260 mm
3
 volume. Gemcitabine was 
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formulated at 40, 20, and 10 mg/mL concentrations by diluting gemcitabine hydrochloride 
(APP Pharmaceuticals, LLC) powder in normal saline. A constant direct current (DC) power 
supply was used to provide 2 mA current to the device. The positive lead was connected to 
the device wire, and the negative lead was connected to the counter electrode placed on the 
mouse's skin. A syringe pump was used to circulate the gemcitabine solution through the 
device at a flow rate of 10 µL/min over a period of 10 minutes. When the device was 
powered, drug was driven from the device reservoir, through the membrane and into the 
tumor tissue following the path of the electrical current. Upon completion of the treatment, 
the device was emptied of drug solution. For PK studies, terminal bleeds were performed. 
The tissue and device were extracted and snap frozen with liquid nitrogen and stored at -80 
°C. Tetrahydrouridine (THU) solution (Calbiochem) was added to the blood, and the blood 
was centrifuged at 11,000 rpm for 10 minutes. The plasma was collected and stored at -80 
°C. For the IV treatment arm of the study, mice were given a single dose of gemcitabine at 80 
mg/kg, and the tissue was removed ten minutes post-infusion. For efficacy studies, the mice 
were treated up to 6 weeks using device with 40 mg/mL gemcitabine concentration, device 
with normal saline (0.9% NaCl), or IV gemcitabine (80 mg/kg).  
 
2.5.3 Testing in Canine Model 
The canine model was housed at Synecor LLC and treated according to Synecor 
IACUC protocol. The dogs weighed between 20-23 kilograms and were between 1-2 years 
old. The dogs were anesthetized, and the abdomen was shaven and cleaned prior to surgery. 
A laparotomy was performed, and the right lobe of the canine pancreas was exposed. The 
devices were implanted on the pancreas, ensuring good contact with the tissue. The device 
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was attached to a power supply, with the positive output attached to the wire connected to the 
silver electrode and the negative output attached to the cathode. A 5”x7” electrocautery patch 
was used as the cathode and was covered with gel and placed onto the back of the animal. A 
1-gram vial of Gemzar® (Eli Lilly) was solubilized in 25 mL of saline, and the 25 mL was 
diluted to 100 mL (pH between 4 and 5). Using an IV infusion pump, the solution was 
pumped through the device at a flow rate of 1.5 mL/min over a period of 60 minutes. Upon 
drug flow through the device, a constant current of 10 mA was applied for 60 minutes. 10mL 
of blood was sampled at 15 minutes increments prior to and during therapy and collected into 
heparinized tubes with 40 µL of a 10 mg/mL tetrahydrouridine (THU) solution. Upon 
completion of the 60 minutes, the device was emptied of drug solution. The dogs were 
euthanized with potassium chloride solution, and the tissue and device were extracted and 
snap frozen with liquid nitrogen and stored at -80 °C. The blood was centrifuged at 2,000 
rpm for 10 minutes, and the plasma was collected and stored at -80 °C. 
 
2.5.4 Processing of Tissue and Plasma 
The frozen tissue was sectioned by a Leica cryostat microtome at -20 °C. The tissue 
was sectioned at 50 µm increments up to one centimeter away from the electrode. Frozen 
tissue sections were combined to reduce the sample number. To the specimens, the internal 
standard, 2’dC, was added at a concentration of 20 µg/mL. To the specimens, 0.08 mg/mL 
THU, 0.4 M perchloric acid solution was added at a liquid to mass ratio of 3:1 (v/w). The 
samples were vortexed and sonicated in an ice bath for 10 minutes. The samples were 
centrifuged at 4,000 rpm for 10 minutes, the pellet was washed with 0.4 M perchloric acid 
and centrifuged again at 4,000 rpm for 10 minutes, and the supernatants were combined. 
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Potassium hydroxide was added to bring the pH to 3 and the insoluble salt, potassium 
perchlorate, was removed by centrifugation. The supernatant was analyzed by UV-HPLC. To 
the plasma samples, 2’dC was added for a concentration of 20 µg/mL. 2.0 M perchloric acid 
was added to the sample at 10 %v/v of the sample. The samples were vortexed, incubate on 
ice for 15 minutes, and centrifuged at 16,000 rpm at 4 °C for 10 minutes. Potassium 
hydroxide was added to bring the pH to 3 and the insoluble salt, potassium perchlorate, was 
discarded. A portion of the solution was analyzed by UV-HPLC. 
 
2.5.5 UV-High Performance Liquid Chromatography Assay 
An Agilent 1200 UV-HPLC was used to quantify the amount of drug in the sectioned 
tissue. An isocractic method using a mobile phase of 90% aqueous buffer (50.0 mM sodium 
phosphate and 3.0 mM sodium octyl sulfate) and 10% acetonitrile brought to pH 2.9 with o-
phosphoric acid, which was developed from Kirstein and colleagues [23]. The stationary 
phase was a Waters Spherisorb ODS2 4.6x250 mm column. The internal standard, 2’dC, and 
gemcitabine were detected at 267 nm, and the run time for the UV-HPLC assay was 15 
minutes. The peaks areas were integrated, and the concentration of gemcitabine was 
determined by reference to validated calibration curves. The calibration curves were created 
by plotting known concentrations of gemcitabine to the ratio of the absorbance of 
gemcitabine to the absorbance of the internal standard. For assay validation, two calibrations 
curves were created each day for three days with six series of quality control standards for 
each calibration curve.  
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2.5.6 Statistical Analysis 
Wilcoxon Rank Sum tests were used to obtain sample size numbers for the canine 
experiments. As the data were normally distributed, t-tests were used for statistical analysis 
of data.  
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Figure 2.1. Iontophoretic devices used for the delivery of gemcitabine to solid tumors. (A) 
Front and side images of an implantable device and (B) the corresponding assembly. Animal 
treatment setups in the (C) pancreatic cancer models where the drug is supplied to the device 
using a syringe pump and electrical current via a DC power supply. Positive and negative 
leads connect to the device (anode) and counter electrode (cathode). Device parameters 
including (D) drug influx rate, (E) electrode material, (F) applied current, and (G) drug 
concentration were evaluated for drug delivered in tissue surrogates (2 wt% agarose). * P < 
0.05, ** P < 0.01, *** P < 0.001, and **** P < 0.0001. 
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Figure 2.2. Role of current on drug transport in ex vivo human tissue. Gemcitabine transport 
through PDX tumor tissue as a function of current – 2 mA of current was applied for 10 
minutes compared to passive diffusion control (n = 6 per treatment group). **P < 0.01. 
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Figure 2.3. PK of gemcitabine delivered by iontophoretic devices into an orthotopic PDX 
model of pancreatic cancer. Mice (n = 3 - 5 per group) were administered a single treatment 
of gemcitabine through the device. Organs were collected from each animal at various times, 
and total gemcitabine concentrations were analyzed (mean ± SEM). Limit of gemcitabine 
quantitation was 1 μg/mL. 
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Figure 2.4. Therapeutic effect of gemcitabine delivered iontophoretically in a pancreatic 
cancer PDX model. (A) Efficacy of device gemcitabine, IV gemcitabine, device saline and 
IV saline in PDX mice treated twice a week for 7 weeks. Data are fold change in tumor 
volume (log2) (n = 7 for IV and device gemcitabine, n = 5-6 for IV and device saline). (B) 
Histological staining of the tumors for Ki-67 at 10X. NS – not significant, **** P < 0.0001. 
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Figure 2.5. Evaluation of single device treatments in a large animal model. (A) Canine 
device to be implanted directly onto the pancreas. (B) Plasma PK of gemcitabine during the 
single device treatment. Organs were removed 1 hour after the initiation of treatment and 
gemcitabine content was quantified. (C) Amount of gemcitabine in the pancreas of dogs after 
the administration of a single device treatment using 40 mg/mL or 10 mg/mL gemcitabine or 
IV gemcitabine (1 g/m2). (D) Distance of gemcitabine transport away from the device and 
into the pancreatic tissue. Data are means ± SEM, NS – not significant, * P < 0.05, *** P < 
0.001. 
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CHAPTER 3: LOCAL IONTOPHORETIC ADMINISTRATION OF CISPLATIN 
FOR THE TREATMENT OF BREAST CANCER  
 
3.1 Overview  
Parenteral and oral routes have been the traditional methods of administering 
cytotoxic agents to cancer patients. Unfortunately, the maximum potential effect of these 
cytotoxic agents has been limited due to systemic toxicity and poor tumor perfusion. In an 
attempt to improve the efficacy of cytotoxic agents while mitigating their side effects, we 
have developed modalities for the localized iontophoretic delivery of cytotoxic agents. These 
pressurized, reservoir-based iontophoretic devices were designed to be implanted proximal to 
the tumor with external control of power and drug flow. Two distinct orthotopic mouse 
models of cancer were evaluated for device efficacy and toxicity. In the mouse models, 
device delivery of cytotoxic agents resulted in enhanced drug accumulation in the tumor and 
tumor shrinkage. These devices have potential paradigm shifting implications for the 
treatment of breast, pancreatic, and other solid tumors. 
 
3.2 Introduction 
Chemotherapy has had an immeasurable impact on the field of oncology with its 
inception in the 1940s [1]. Cytotoxic and molecularly-targeted agents have become the 
mainstay of cancer therapy [2]. However, the maximum potential effect of these therapies 
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has not been achieved due to secondary toxicities associated with systemic delivery. Many 
systemically administered chemotherapies place patients at high risk for infection, organ 
damage, and disability [3]. Furthermore, certain types of solid tumors, such as pancreatic, are 
perfusion limited [4]. Dense stromal environments and poor vascularization impede 
diffusion, reducing drug exposure to the primary tumor [5-7]. This impaired drug delivery 
has contributed to the dreadful prognosis and lack of significant clinical advancements in 
treatment of certain solid tumors [4,6-7]. To improve the efficacy of chemotherapies and 
mitigate their side effects, new drug delivery strategies are necessary to concentrate the drug 
in the tumor site while sparing off-target tissue toxicities.  
Local drug delivery technologies offer a promising alternative to systemic delivery. 
They exist in a variety of form factors designed to facilitate the delivery of drug directly to 
the site of disease in a controlled manner. Many of these are biodegradable polymeric depots 
designed to maintain therapeutic concentrations of drug at the tumor site for a prolonged 
period of time. However, only a small subset of these technologies has demonstrated 
potentially curative preclinical results for cancer applications, and far fewer have progressed 
toward clinical practice. A key challenge of many of these local drug delivery systems, 
particularly polymeric-drug eluting technologies like the Gliadel wafer, has been diffusion 
limitations [8]. The lack of spatial distribution of drugs and elevated interstitial fluid 
pressures in solid tumors have relegated the use of many local drug delivery systems to post-
surgical therapy [9]. A subset of local drug delivery devices involves the use of electric fields 
to drive drugs into the area of greatest need in a technique known as iontophoresis. 
Iontophoretic devices are capable of overcoming diffusion barriers by electrorepulsive and 
electroosmotic forces [10-12]. Advances in urologic and ophthalmologic devices have 
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enabled the effective iontophoretic delivery of mitomycin C and dexamethasone to tissues 
while reducing the systemic effects of these drugs [13-16]. Here, we developed and 
investigated a new iontophoretic device platform for the local delivery of cytotoxic therapies 
to solid tumors. These pressurized, reservoir-based iontophoretic devices were designed to be 
implanted proximal to the tumor with external user control of power and drug flow. 
To evaluate the broad application of these iontophoretic devices as potential anti-
cancer therapies, we elected to test the devices in a diverse set of orthotopic breast cancer 
models [17-20]. We describe an in-depth preclinical characterization of iontophoretic 
delivery of cytotoxic agents. We report that these devices deliver high levels of cytotoxic 
drugs, reduce systemic exposure of the drugs, and potently impact tumor growth. These 
devices offer an entirely new modality for the treatment of cancer. 
 
3.3 Results  
3.3.1 Device Development 
Our devices were designed to adapt conventional iontophoretic drug delivery 
techniques. Figure 3.1A-C showcases the device, the assembly, and the setup for animal 
treatments. The devices were composed of a polydimethylsiloxane reservoir, a silver 
electrode, and an inlet and outlet for continuous drug flow through the reservoir. This 
continuous drug flow maintained a constant drug concentration around the electrode and 
pressure within the device. Under an applied electric potential, the drug was transported in 
the direction normal to the electrode and into the tissue. 
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3.3.2 Drug Transport in Human Tissue 
The transport of cisplatin into ~1 mm thick ex vivo human skin was evaluated using a 
modified Franz diffusion cell with the device directly above the skin instead of a donor 
chamber. One or 0 mA of current was applied for 25 minutes, and the skin and solution were 
snap frozen, processed, and analyzed by inductively coupled plasma-mass spectrometry 
(ICP-MS). The application of current resulted in an 11.4-fold increase in platinum 
transported into the human skin compared to passive diffusion (Figure 3.2). In the receptor 
compartment, we found 24.8 ± 18.8 ng/mL platinum when current was applied but no 
detectable amount of platinum for the passive diffusion control. Murine skin was evaluated 
using the same method revealing similar drug transport into the skin but larger transport 
through the skin.  
 
3.3.3 Pharmacokinetics and Biodistribution of Cisplatin  
Figure 3.3 shows a typical study in which the device delivery of cisplatin was 
evaluated in an orthotopic SUM149 xenograft model of breast cancer. The concurrent device 
and IV delivery of cisplatin was added as an arm of the study based upon the low systemic 
exposure of cisplatin after device treatments. A single treatment was administered after 
adhesion of the device to the skin above the tumor. Platinum plasma exposure as measured 
by AUC of the concentration vs time curve for device delivery, IV, and device + IV delivery 
were 2.0, 9.9, and 10.7 hr*µg/mL, respectively. In addition, tumor AUC for device, IV (5 
mg/kg), and device + IV (5 mg/kg) delivery were 30.2, 42.4, and 83.4 hr*µg/g, respectively. 
Furthermore, there were significant differences in cisplatin accumulation in the left inguinal 
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mammary, kidney, skin, inguinal lymph node, and right inguinal mammary for the two 
different routes of cisplatin administration. 
 
3.3.4 Device Efficacy 
This platform technology was further evaluated in orthotopic breast cancer models – 
SUM149 xenograft and T11 syngeneic models (Figure 3.4). In both models, we compared 
the efficacy of device cisplatin, IV cisplatin, device + IV cisplatin, device saline, and IV 
saline (Figure 3.4A-B and D-E). Once the SUM149 xenograft tumors reached ~50 mm
3
, the 
mice were treated with device cisplatin, IV cisplatin (5 mg/kg), device + IV cisplatin (5 
mg/kg), device saline, or IV saline every week for a total of four doses. Mice bearing T11 
tumors received two doses of the same test arms 1 week apart beginning 5 days after 
inoculation (~20 mm
3
). The number of treatments varied across different tumor models 
owing to differences in tolerability of treatments. Device cisplatin and IV cisplatin both 
resulted in significant tumor growth inhibition compared to the controls in the SUM149 (p = 
0.0002) and T11 models (p < 0.0001) (Figure 3.4A and E). Device + IV cisplatin resulted in 
significant tumor growth inhibition, outperforming device cisplatin and IV cisplatin in both 
tumor models (p = 0.0002). We also assessed the effects of device treatment on overall 
survival in the tumor models. Device cisplatin, IV cisplatin, and device + IV cisplatin 
extended the lifespan from a median of 49 days to 60, 68, and past 100 days, respectively, in 
the SUM149 model (p < 0.0001) (Figure 3.4B). Device cisplatin, IV cisplatin, and device + 
IV cisplatin extended the lifespan from a median of 10 days to 20, 22, and 32 days, 
respectively, in the T11 model (p < 0.0001) (Figure 3.4D). The skin of the mice after four 
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weekly device treatments showed no scarring or deformation (Figure 3.4C). Device cisplatin 
was better tolerated based on histological staining of the kidneys for a sensitive molecular 
marker of DNA damage and repair, γH2AX, compared to IV cisplatin and device + IV 
cisplatin (Figure 3.5). In addition, histological samples from tumors post treatment revealed 
almost equivalent γH2AX staining from device cisplatin and IV cisplatin-treated mice and 
greater γH2AX staining in device + IV cisplatin-treated mice (Figure 3.4F).  
We next determined whether the addition of radiotherapy to the device delivery of 
cisplatin, a well-known radiosensitizing agent, could improve the therapeutic effect of the 
treatment. Mice bearing orthotopic T11 tumors received a single dose of the radiation (10 
Gy), device cisplatin, device cisplatin + radiation (10 Gy), IV cisplatin (5 mg/kg), IV 
cisplatin + radiation (10 Gy), device + IV cisplatin (5 mg/kg), or device cisplatin + IV 
cisplatin (5 mg/kg) + radiation (10 Gy) 5 days after inoculation (~20 mm
3
). There were three 
major cohorts of response (Figure 3.4G and H). Mice treated with a single dose of radiation, 
device cisplatin, or IV cisplatin resulted in similar tumor growth rates and survival; compared 
to the no treatment control, a single dose of radiation, device cisplatin, or IV cisplatin 
resulted in significant tumor growth inhibition (p < 0.0001) and survival (p < 0.0001). Mice 
treated with a single dose of device cisplatin + radiation, IV cisplatin + radiation, or device + 
IV cisplatin also resulted in similar tumor growth rates and survival; compared to the 
radiation, device cisplatin, and IV cisplatin treatments, a single dose of device cisplatin + 
radiation, IV cisplatin + radiation, or device + IV cisplatin resulted in significantly greater 
tumor growth inhibition (p < 0.0001) and survival (p < 0.0001), indicating that the addition 
of radiotherapy to the device and IV treatments improved tumor growth inhibition. Device + 
IV cisplatin + radiation outperformed all other treatment groups in tumor growth inhibition 
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and survival; compared to the device cisplatin + radiation, IV cisplatin + radiation, and 
device + IV cisplatin treatments, a single dose of device + IV cisplatin + radiation resulted in 
non-statistically significant tumor growth inhibition (p = 0.084) but significantly greater 
survival (p < 0.0002). Overall, the addition of radiation to device cisplatin, IV cisplatin, and 
device + IV cisplatin significantly improved survival (p < 0.0001). 
 
3.4 Discussion 
It is believed that local delivery of chemotherapies will have a revolutionary impact 
on the treatment of cancer by maximizing the effect at the target site and sparing off-target 
tissue toxicities [9]. Despite this belief, the translation of the local drug delivery technologies 
from basic research into everyday cancer treatments has remained elusive. We decided to 
take an iontophoretic approach to address the issue that plagues the success of these 
technologies – limited drug penetration. Iontophoresis is capable of overcoming considerable 
flow and pressure gradients, particularly those found in solid tumors [13]. In addition, a large 
number of small molecule drugs are capable of being delivered by iontophoresis [15, 21-23]. 
Here, we show that iontophoretic devices can deliver substantial amounts of drugs to 
the site of interest with limited systemic exposure. Our preclinical results suggest that device 
delivery of cisplatin may potentiate the current treatment of solid tumors by enhancing the 
therapeutic index of the drugs. In addition, the co-administration of systemic therapy, device 
therapy, and radiotherapy proved feasible and significantly improved tumor growth 
inhibition and survival in breast cancer models.  
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Although our iontophoretic devices enable significant local drug transport, their 
efficacy could be further improved by potentially altering the dosing schedule, optimizing 
drug formulations, and configuring the device according to tumor shape and surrounding 
anatomy. Because of the high drug concentrations in the tumor and low level of systemic 
exposure after a single treatment, the number of device treatments could be increased. Drug 
formulation plays an important role in the iontophoretic delivery of drugs through competing 
ions and electroosmotic flow, and the evaluation of formulation excipients could improve 
total drug delivered and distance of drug transport [24]. Configuring these devices to fit the 
shape of the tumor and surrounding anatomy would improve efficacy by creating better 
contact between the device and tumor tissue and, in the case of pancreatic cancer, 
strategically delivering the cytotoxic agents to the area that would enable tumor resection. 
Furthermore, some key parameters that need to be understood for success in the clinic are the 
adequacy of drug penetration for humans and the scaling of the treatment to address larger 
human tumors.  
 
3.5 Materials and Methods 
3.5.1 Device Fabrication 
Iterative device design was performed using a 3D computer-aided design software 
(SolidWorks). An 8.6 mm silver disc was soldered to a 36-gauge copper wire and embedded 
in a polydimethylsiloxane (Sylgard 184) reservoir prior to crosslinking. The copper wire was 
thread through one multi-luminal tube, and the tube was inserted into the reservoir for influx 
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of drug. Another multi-luminal tube was inserted on the contralateral side of the reservoir for 
drug efflux.  
 
3.5.2 Ex Vivo Studies 
De-identified human skin was provided by the cooperative human tissue network. 
The frozen skin was thawed and sectioned into 2 x 2 cm squares prior to drug transport 
studies. The transport of cisplatin in skin was evaluated using a modified Franz diffusion cell 
with the device directly above the skin. The receptor chamber was filled with 5mL of normal 
saline. One or 0 mA of current was applied for 25 minutes, and the skin and solution were 
snap frozen, processed by nitric acid, and analyzed by ICP-MS. 
 
3.5.3 Animal Studies 
All procedures were approved by the appropriate Institutional Animal Care and Use 
Committee before initiation. All animals used in PK, biodistribution, and efficacy studies 
were allowed to acclimate for at least 1 week in the animal facilities before experimentation. 
Animals were exposed to a 12-hour light/dark cycle and received food and water ad libitum 
through the studies. For quantitation of cisplatin plasma concentrations, blood samples were 
collected into lithium heparin tubes and plasma was generated and frozen with liquid 
nitrogen; tissue and device were extracted and snap frozen with liquid nitrogen and stored at 
-80 °C. Total platinum was extracted from frozen plasma and organs using a nitric acid 
degradation method and analyzed by ICP-MS [25].  
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3.5.4 PK Studies 
Five million SUM149 cells resuspended in Matrigel (50:50) were injected into the left 
inguinal mammary fat pad of 4-8 week old athymic nude mice. Devices were transdermal 
adhered onto the skin (3M Vetbond) above the orthotopic tumors when they reached a single 
dimension of 5-7 mm. The cisplatin solutions used for device delivery were formulated at pH 
5.9 (APP Pharmaceuticals, LLC), and the cisplatin used for IV delivery was administered 
directly from the clinical formulation. A constant DC power supply was used to provide 
power to the device. The positive lead was connected to the device wire, and the negative 
lead was connected to a silver chloride electrode placed on the mouse's skin with electrolyte 
gel. A syringe pump was used to circulate the cisplatin solution through the device at a flow 
rate of 50 µL/min over a period of 10 minutes. When the device was powered, drug was 
driven from the device reservoir, through the membrane and into the tumor tissue following 
the path of the electrical current. Upon completion of the treatment, the device was emptied 
of drug solution. Terminal bleeds were performed. The mice were treated with a single 
transdermal iontophoretic dose of cisplatin or 5 mg/kg bolus of cisplatin via tail vein. Plasma, 
tumor, skin, kidney, left and right inguinal mammary glands, and inguinal lymph node were 
collected at 0.5, 1, 6, and 24 hours after administration.  
 
3.5.5 Efficacy Studies  
The technical protocol for device treatments was identical to the PK studies. Mice 
were treated two or four times weekly using device cisplatin, IV cisplatin (5 mg/kg), device + 
IV (5 mg/kg) cisplatin, device saline (0.9% NaCl), or IV saline. Tumors derived from 
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BALB/cTP53
-/-
 orthotopic mammary gland transplant line (T11) were passage in BALB/c 
wild-type mice by subcutaneous injection of five hundred thousand cells resuspended in 
matrigel (50:50) into the left inguinal mammary gland. The day before scheduled treatment, 
the mice were shorn with clippers, and the residual hair was removed using Nair. For the 
radiation studies, at two hours post injection, the tumors were subjected to a dose of 10 Gy 
with XRAD 320. Mice were shielded with a specially designed lead cover allowing 
irradiation of the tumor site and minimal radiation to other organs. 
 
3.5.6 PK and Statistical Analyses 
PK parameters were assessed with Phoenix WinNonLin (version 6.0). Analysis of 
variance methods (ANOVA), using generalized linear models, were used to make 
comparisons of continuous values between groups. Pairwise comparisons were made when 
an overall difference was detected. For figure 5A, D, and G, comparisons were made 
between groups at two time points: 1) when all mice were still alive (day 28, 9, 9) and 2) 
when all mice on treatment were still alive (day 42, 16, 15). AUC was used as the summary 
measure for figure 6B, and comparisons were made use ANOVA as well.  For survival data, 
the Kaplan Meier method and Log-rank tests were used to make comparisons between 
groups. Unadjusted p-values are reported for pairwise comparisons, when an overall 
difference was detected. All analyses were done using SAS v9.3 (Cary, NC).   
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Figure 3.1. Iontophoretic devices used for the delivery of cisplatin to solid tumors. (A) front 
and side images of a transdermal device, and (B) the corresponding assemblies. Animal 
treatment setups in the (C) breast cancer models where the drug is supplied to the device 
using a syringe pump and electrical current via a DC power supply. Positive and negative 
leads connect to the device (anode) and counter electrode (cathode). 
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Figure 3.2. Role of current on drug transport in ex vivo human tissue. Cisplatin transport 
through human skin as a function of current – 1 mA of current was applied for 25 minutes 
compared to passive diffusion control (n = 5 per treatment group). **** P < 0.0001. 
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Figure 3.3. PK of cisplatin delivered by iontophoretic devices into SUM149 orthotopic 
xenografts of breast cancer. Mice (n = 5 per group) were administered a single treatment of 
cisplatin through the device. Organs were collected from each animal at various times, and 
total platinum concentrations were analyzed (mean ± SEM). Limit of platinum quantitation 
was 5 ng/mL. 
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Figure 3.4. Therapeutic effect of cisplatin delivered iontophoretically in mouse tumor 
xenograft and syngeneic models of breast cancer. (A) Efficacy and (B) survival of device 
cisplatin, IV cisplatin, device + IV cisplatin, device saline and IV saline in the SUM149 
tumor xenograft model treated once a week for a total of four doses (n = 8 – 9 per treatment 
group). (C) Representative images of murine skin before and after four weeks of device 
treatment. (D) Efficacy and (E) survival of device cisplatin, IV cisplatin, device + IV 
cisplatin, device saline and IV saline in the T11 syngeneic model treated once a week for a 
total of two doses (n = 9 per treatment group). (F) Histological staining of tumors for γH2AX 
(4X) harvested from SUM149 tumor xenografts 24 hours after a single treatment and 
quantification of γH2AX staining according to H-score. Next, we evaluated the 
combinatorial effect of radiation and IV cisplatin, device cisplatin, or IV + device cisplatin in 
the T11 syngeneic model. (G) Efficacy and (H) survival after a single treatment of no 
treatment control, radiation, device cisplatin, device cisplatin + radiation, IV cisplatin, IV 
cisplatin + radiation, device + IV cisplatin, or device + IV cisplatin + radiation (n = 8 per 
treatment group). Data are mean tumor volumes ± SEM. NS – not significant, ** P < 0.01, 
*** P < 0.001, and **** P < 0.0001. 
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Figure 3.5. Pharmacological evaluation of the short-term renal toxicity after a single device 
cisplatin treatment. (A) Platinum-DNA adducts and (B) γH2AX staining within the kidney in 
a SUM149 breast cancer xenograft model (n = 5 per group). Organs were collected from each 
animal at 6 and 24 hours. 
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CHAPTER 4: CONCLUSIONS AND FUTURE DIRECTIONS 
 Here, we show that iontophoretic devices can deliver substantial amounts of drugs to 
the site of interest with limited systemic exposure. Our preclinical results suggest that device 
delivery of gemcitabine and cisplatin may potentiate the current treatment of solid tumors by 
enhancing the therapeutic index of the drugs. In addition, the co-administration of systemic 
therapy, device therapy, and radiotherapy proved feasible and significantly improved tumor 
growth inhibition and survival in breast cancer models. 
For future studies, the implantable devices should be redesigned to address key issues 
of gas formation on the electrode, protein buildup on the reservoir membrane, device 
anchoring onto tumors, and time requirements for device fabrication. The electrochemistry of 
Pt electrodes produces significant gas pockets that limit the transport of drug and increase the 
voltage necessary to maintain a constant current. Disruption of the bubbles through physical 
measures would facilitate greater drug transport and reduce the potential for animals or 
patients to experience electrical shocks during the treatment. Separation of the inlet and 
outlet could also improve removal of the bubbles and filling of the drug reservoir. Secondly, 
the reservoir membrane used within these studies was a 12 kDa cellulose membrane, and for 
future work, a polytetrafluoroethylene membrane with the same molecular weight cutoff 
should be considered to reduce protein buildup on the membrane. Furthermore, flaps could 
be incorporated into the device to allow for suturing the device onto the solid tumor, in order 
to keep the sutures away from the central device reservoir. Device size and shape could play 
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a significant role in the effectiveness of drug delivery. Three-dimensional (3D) printing of 
the device according to computed tomographic imaging of the tumor could be helpful in 
fitting the device to the patient’s anatomy [1]. Important considerations for the 3D printing of 
the device include the ability to incorporate the metallic electrode within the device and 
adhesion of the membrane on the device. Post-fabrication processing steps would be 
necessary to thread the electrode through an opening of the printed device, seal the device 
using a physical or chemical process, and adhere the membrane on the device reservoir. 
Addressing these key issues would potentially improve drug transport from a reservoir-based 
iontophoretic device.  
A thorough safety evaluation will be necessary in progressing towards human trials. 
Evaluation of damage on normal tissue surrounding the implantation and device treatments 
sites will need to be performed in large animals. For the transdermal delivery of a cytotoxic 
agent, one would need to follow-up on long-term ramifications of local skin irritation and the 
possibility of scar formation. Determining systemic exposure as a function of device surface 
area will be important to understand the device size constraints. Furthermore, delineating 
drug versus device effects will be necessary in identifying the functionality of the drug-
device combination. Safety evaluation of the device in combination with radiation and 
systemic chemotherapy could also be necessary as the treatment would likely be used in 
combination with other therapies.   
With the ability to locally deliver toxic regimens to solid tumors, it may be possible to 
evaluate the delivery of abandoned drugs and less water-soluble drugs. Güngör et al. 
evaluated the delivery of less soluble drugs by using organic/aqueous solutions [2]. Similar to 
Sethi et al., the use of wortmannin and other such drugs could improve radio-sensitivity of 
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the drugs while reducing toxicity [3]. Peptide and protein delivery is also feasible and could 
potentially allow for an immunomodulatory component of the device treatment [4]. 
Furthermore, alternative device embodiments should be evaluated, such as intravascular and 
endoscopic approaches (Figure 4.1).  
Overall, the challenge of using iontophoresis for the treatment of cancer is identifying 
the right drug–disease combination for which iontophoresis represents real added-value over 
and above the existing approach and alternative options. A prime example outside of 
oncology is the delivery of lidocaine. Iontophoresis is able to induce local anesthesia much 
faster than a typical, topical cream, but the use of the device is more complex, requiring more 
health professional time to set up and explain to the patient, and is more expensive. 
Therefore, will shortening of time required for the pharmacological effect to be induced a 
sufficient benefit to outweigh the less positive features? In the field of oncology, 
iontophoretic devices could play an important role as an adjunct therapy. The addition of the 
iontophoretic device delivery to systemic therapy could build upon the recent success of 
FOLFIRINOX and gemcitabine + abraxane in the treatment of metastatic pancreatic cancer.   
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Figure 4.1. Iontophoretic devices for the treatment of internal body cancers. 
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